SCHEMBL1629562

SCHEMBL1629562

CC1(C)OB(c2ccc3ccc4c5cc(B6OC(C)(C)C(C)(C)O6)ccc5ccc4c3c2)OC1(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 13/20 0.51
LIPG Q9Y5X9 13/20 0.51
IRAK4 Q9NWZ3 1/20 0.42
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CSF1R P07333 1/20 0.40
CA12 O43570 1/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
F11 P03951 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1628014 0.95 LPL (0.47) LPLLIPGIRAK4CA1CA2
SCHEMBL13330818 0.92 LPL (0.45) LPLLIPGIRAK4CA1CA2
SCHEMBL17268981 0.92 LPL (0.56) LPLLIPGIRAK4PRMT5WDR77
SCHEMBL13331252 0.89 LPL (0.43) LPLLIPGIRAK4CSF1RPRMT5
SCHEMBL1627177 0.89 LPL (0.51) LPLLIPGIRAK4CA1CA2
SCHEMBL2453344 0.87 LPL (0.59) LPLLIPGIRAK4PRMT5WDR77
SCHEMBL29444278 0.87 LPL (0.59) LPLLIPGIRAK4PRMT5WDR77
SCHEMBL6126262 0.86 LPL (0.53) LPLLIPGIRAK4CA1CA2
SCHEMBL12230674 0.85 LPL (0.40) LPLLIPGIRAK4CA1CA2
SCHEMBL21764502 0.85 LPL (0.56) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379473-B1 DIACENAPHTHO[1,2-B:1',2'-K]CHRYSENE DERIVATIVE CANON KK (JP) 2017-02-22 EP disclosed
US-8951648-B2 Diacenaphtho[1,2-b:1′,2′-k]chrysene derivative CANON KABUSHIKI KAISHA (JP) 2015-02-10 US disclosed
US-8951648-B2 Diacenaphtho[1,2-b:1′,2′-k]chrysene derivative CANON KABUSHIKI KAISHA (JP) 2015-02-10 US disclosed
US-8519613-B2 Organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2013-08-27 US disclosed
US-8519613-B2 Organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2013-08-27 US disclosed
US-20120085996-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2012-04-12 US disclosed
US-20120085996-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2012-04-12 US disclosed
US-8102116-B2 Organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-01-24 US disclosed
US-8102116-B2 Organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-01-24 US disclosed
US-20120013700-A1 NOVEL FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2012-01-19 US disclosed
US-20120013700-A1 NOVEL FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2012-01-19 US disclosed
US-20110315973-A1 NOVEL FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2011-12-29 US disclosed
US-20110315973-A1 NOVEL FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2011-12-29 US disclosed
US-20110251446-A1 DIACENAPHTHO[1,2-b:1',2'-k]CHRYSENE DERIVATIVE CANON KABUSHIKI KAISHA (JP) 2011-10-13 US disclosed
US-20110251446-A1 DIACENAPHTHO[1,2-b:1',2'-k]CHRYSENE DERIVATIVE CANON KABUSHIKI KAISHA (JP) 2011-10-13 US disclosed
US-20100157131-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-06-24 US disclosed
US-20100157131-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-06-24 US disclosed
WO-2010071224-A1 DIACENAPHTHO[1,2-b:1',2'-k]CHRYSENE DERIVATIVE CANON KABUSHIKI KAISHA (JP) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110315973-A1 NOVEL FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE NR2E3, PYM1, TYR LPL 2431/4885LIPG 3493/4885IRAK4 1937/4885
US-20110251446-A1 DIACENAPHTHO[1,2-b:1',2'-k]CHRYSENE DERIVATIVE DNAJB12, DNAJA1, DNAJA2 LPL 4849/4885LIPG 4558/4885IRAK4 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.